APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neuraminidase Inhibitors Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neuraminidase Inhibitors Drug Industry Growth and Trends Forecast to 2032

Report ID 17401640012 January 202685 pages

Choose your research edition.

Industry ResearchNeuraminidase Inhibitors Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuraminidase Inhibitors Drug Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Neuraminidase Inhibitors Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuraminidase Inhibitors Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuraminidase Inhibitors Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

According to APO Research, the global Neuraminidase Inhibitors Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Neuraminidase Inhibitors Drug market include Teva, Roche, Pfizer, GSK, AstraZeneca, Sun Pharmaceutical, Gilead Sciences, Daiichi Sankyo and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neuraminidase Inhibitors Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neuraminidase Inhibitors Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neuraminidase Inhibitors Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neuraminidase Inhibitors Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Neuraminidase Inhibitors Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neuraminidase Inhibitors Drug Market by Company

Teva

Roche

Pfizer

GSK

AstraZeneca

Sun Pharmaceutical

Gilead Sciences

Daiichi Sankyo

Bristol-Myers Squibb

Neuraminidase Inhibitors Drug Segment by Type

Oseltamivir

Laninamivir

Peramivir

Zanamivir

Neuraminidase Inhibitors Drug Segment by Application

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Others

Neuraminidase Inhibitors Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitors Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitors Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitors Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Neuraminidase Inhibitors Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Neuraminidase Inhibitors Drug Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Neuraminidase Inhibitors Drug Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Neuraminidase Inhibitors Drug Market Share by Region (2021-2026) Table 4. Global Neuraminidase Inhibitors Drug Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Neuraminidase Inhibitors Drug Market Share by Region (2027-2032) Table 6. Global Neuraminidase Inhibitors Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Neuraminidase Inhibitors Drug Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Neuraminidase Inhibitors Drug Market Size Share by Type (2021-2026) Table 9. Global Neuraminidase Inhibitors Drug Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Neuraminidase Inhibitors Drug Market Size Share Forecasted by Type (2027-2032) Table 11. North America Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Neuraminidase Inhibitors Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Neuraminidase Inhibitors Drug Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Neuraminidase Inhibitors Drug Market Size Share by Application (2021-2026) Table 24. Global Neuraminidase Inhibitors Drug Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Neuraminidase Inhibitors Drug Market Size Share Forecasted by Application (2027-2032) Table 26. North America Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Neuraminidase Inhibitors Drug Industry Trends Table 37. Neuraminidase Inhibitors Drug Industry Drivers Table 38. Neuraminidase Inhibitors Drug Industry Opportunities and Challenges Table 39. Neuraminidase Inhibitors Drug Industry Restraints Table 40. Global Neuraminidase Inhibitors Drug Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Neuraminidase Inhibitors Drug Revenue Market Share by Company (2021-2026) Table 42. Global Neuraminidase Inhibitors Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Neuraminidase Inhibitors Drug Key Company Headquarters & Area Served Table 44. Global Neuraminidase Inhibitors Drug Company, Product Type & Application Table 45. Global Neuraminidase Inhibitors Drug Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Neuraminidase Inhibitors Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Teva Company Information Table 49. Teva Business Overview Table 50. Teva Neuraminidase Inhibitors Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Teva Neuraminidase Inhibitors Drug Product Portfolio Table 52. Teva Recent Development Table 53. Roche Company Information Table 54. Roche Business Overview Table 55. Roche Neuraminidase Inhibitors Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Roche Neuraminidase Inhibitors Drug Product Portfolio Table 57. Roche Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Neuraminidase Inhibitors Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Pfizer Neuraminidase Inhibitors Drug Product Portfolio Table 62. Pfizer Recent Development Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Neuraminidase Inhibitors Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. GSK Neuraminidase Inhibitors Drug Product Portfolio Table 67. GSK Recent Development Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Neuraminidase Inhibitors Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. AstraZeneca Neuraminidase Inhibitors Drug Product Portfolio Table 72. AstraZeneca Recent Development Table 73. Sun Pharmaceutical Company Information Table 74. Sun Pharmaceutical Business Overview Table 75. Sun Pharmaceutical Neuraminidase Inhibitors Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Portfolio Table 77. Sun Pharmaceutical Recent Development Table 78. Gilead Sciences Company Information Table 79. Gilead Sciences Business Overview Table 80. Gilead Sciences Neuraminidase Inhibitors Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Gilead Sciences Neuraminidase Inhibitors Drug Product Portfolio Table 82. Gilead Sciences Recent Development Table 83. Daiichi Sankyo Company Information Table 84. Daiichi Sankyo Business Overview Table 85. Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Daiichi Sankyo Neuraminidase Inhibitors Drug Product Portfolio Table 87. Daiichi Sankyo Recent Development Table 88. Bristol-Myers Squibb Company Information Table 89. Bristol-Myers Squibb Business Overview Table 90. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Portfolio Table 92. Bristol-Myers Squibb Recent Development Table 93. North America Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. North America Neuraminidase Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 95. North America Neuraminidase Inhibitors Drug Market Share by Country (2021-2026) Table 96. North America Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. North America Neuraminidase Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 98. Europe Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Europe Neuraminidase Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 100. Europe Neuraminidase Inhibitors Drug Market Share by Country (2021-2026) Table 101. Europe Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Europe Neuraminidase Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 103. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 105. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Country (2021-2026) Table 106. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Asia-Pacific Neuraminidase Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 108. Latin America Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 110. Latin America Neuraminidase Inhibitors Drug Market Share by Country (2021-2026) Table 111. Latin America Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Latin America Neuraminidase Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 113. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 115. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2021-2026) Table 116. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Middle East & Africa Neuraminidase Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Neuraminidase Inhibitors Drug Product Image Figure 3. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 5. Global Neuraminidase Inhibitors Drug Market Share by Region: 2025 VS 2032 Figure 6. Global Neuraminidase Inhibitors Drug Market Share by Region (2021-2032) Figure 7. North America Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Oseltamivir Image Figure 13. Global Oseltamivir Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Laninamivir Image Figure 15. Global Laninamivir Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Peramivir Image Figure 17. Global Peramivir Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Zanamivir Image Figure 19. Global Zanamivir Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Neuraminidase Inhibitors Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Neuraminidase Inhibitors Drug Market Share by Type 2025 VS 2032 Figure 22. North America Neuraminidase Inhibitors Drug Market Size Share by Type (2021-2032) Figure 23. Europe Neuraminidase Inhibitors Drug Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Share by Type (2021-2032) Figure 25. Latin America Neuraminidase Inhibitors Drug Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Neuraminidase Inhibitors Drug Market Size Share by Type (2021-2032) Figure 27. Hospital Pharmacy Image Figure 28. Global Hospital Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Online Pharmacy Image Figure 30. Global Online Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Retail Pharmacy Image Figure 32. Global Retail Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Others Image Figure 34. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Global Neuraminidase Inhibitors Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Neuraminidase Inhibitors Drug Market Share by Application 2025 VS 2032 Figure 37. North America Neuraminidase Inhibitors Drug Market Size Share by Application (2021-2032) Figure 38. Europe Neuraminidase Inhibitors Drug Market Size Share by Application (2021-2032) Figure 39. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Share by Application (2021-2032) Figure 40. Latin America Neuraminidase Inhibitors Drug Market Size Share by Application (2021-2032) Figure 41. Middle East and Africa Neuraminidase Inhibitors Drug Market Size Share by Application (2021-2032) Figure 42. Global Top 5 and 10 Neuraminidase Inhibitors Drug Players Market Share by Revenue in 2025 Figure 43. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 44. North America Neuraminidase Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. North America Neuraminidase Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. North America Neuraminidase Inhibitors Drug Market Share by Country (2021-2032) Figure 47. Europe Neuraminidase Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Neuraminidase Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Neuraminidase Inhibitors Drug Market Share by Country (2021-2032) Figure 50. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Country (2021-2032) Figure 53. Latin America Neuraminidase Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Neuraminidase Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Neuraminidase Inhibitors Drug Market Share by Country (2021-2032) Figure 56. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2021-2032) Figure 59. Years Considered Figure 60. Research Process Figure 61. Key Executives Interviewed

Scope & coverage.

Types
  • Oseltamivir
  • Laninamivir
  • Peramivir
  • Zanamivir
Applications
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others
Companies covered
  • Teva
  • Roche
  • Pfizer
  • GSK
  • AstraZeneca
  • Sun Pharmaceutical
  • Gilead Sciences
  • Daiichi Sankyo
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Neuraminidase Inhibitors Drug Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Neuraminidase Inhibitors Drug Market Size by Region (2021-2032)
  5. 1.4.1 Global Neuraminidase Inhibitors Drug Market Size by Region (2021-2026)
  6. 1.4.2 Global Neuraminidase Inhibitors Drug Market Size by Region (2027-2032)
  7. 1.5 Key Regions Neuraminidase Inhibitors Drug Market Size (2021-2032)
  8. 1.5.1 North America Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate (2021-2032)
2 Neuraminidase Inhibitors Drug Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Oseltamivir
  3. 2.1.2 Laninamivir
  4. 2.1.3 Peramivir
  5. 2.1.4 Zanamivir
  6. 2.2 Global Neuraminidase Inhibitors Drug Market Size by Type
  7. 2.2.1 Global Neuraminidase Inhibitors Drug Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Neuraminidase Inhibitors Drug Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Neuraminidase Inhibitors Drug Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Neuraminidase Inhibitors Drug Market Size by Regions
  11. 2.3.1 North America Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Neuraminidase Inhibitors Drug Market Size Breakdown by Type (2021-2026)
3 Neuraminidase Inhibitors Drug Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital Pharmacy
  3. 3.1.2 Online Pharmacy
  4. 3.1.3 Retail Pharmacy
  5. 3.1.4 Others
  6. 3.2 Global Neuraminidase Inhibitors Drug Market Size by Application
  7. 3.2.1 Global Neuraminidase Inhibitors Drug Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Neuraminidase Inhibitors Drug Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Neuraminidase Inhibitors Drug Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Neuraminidase Inhibitors Drug Market Size by Regions
  11. 3.3.1 North America Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Neuraminidase Inhibitors Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Neuraminidase Inhibitors Drug Industry Trends
  2. 4.2 Neuraminidase Inhibitors Drug Industry Drivers
  3. 4.3 Neuraminidase Inhibitors Drug Industry Opportunities and Challenges
  4. 4.4 Neuraminidase Inhibitors Drug Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Neuraminidase Inhibitors Drug Revenue (2021-2026)
  2. 5.2 Global Neuraminidase Inhibitors Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Neuraminidase Inhibitors Drug Key Company Headquarters & Area Served
  4. 5.4 Global Neuraminidase Inhibitors Drug Company, Product Type & Application
  5. 5.5 Global Neuraminidase Inhibitors Drug Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Neuraminidase Inhibitors Drug Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Neuraminidase Inhibitors Drug Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Neuraminidase Inhibitors Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Teva
  2. 6.1.1 Teva Company Information
  3. 6.1.2 Teva Business Overview
  4. 6.1.3 Teva Neuraminidase Inhibitors Drug Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Teva Neuraminidase Inhibitors Drug Product Portfolio
  6. 6.1.5 Teva Recent Developments
  7. 6.2 Roche
  8. 6.2.1 Roche Company Information
  9. 6.2.2 Roche Business Overview
  10. 6.2.3 Roche Neuraminidase Inhibitors Drug Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Roche Neuraminidase Inhibitors Drug Product Portfolio
  12. 6.2.5 Roche Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Neuraminidase Inhibitors Drug Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Neuraminidase Inhibitors Drug Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK Neuraminidase Inhibitors Drug Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 GSK Neuraminidase Inhibitors Drug Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Neuraminidase Inhibitors Drug Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Neuraminidase Inhibitors Drug Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Sun Pharmaceutical
  32. 6.6.1 Sun Pharmaceutical Company Information
  33. 6.6.2 Sun Pharmaceutical Business Overview
  34. 6.6.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Portfolio
  36. 6.6.5 Sun Pharmaceutical Recent Developments
  37. 6.7 Gilead Sciences
  38. 6.7.1 Gilead Sciences Company Information
  39. 6.7.2 Gilead Sciences Business Overview
  40. 6.7.3 Gilead Sciences Neuraminidase Inhibitors Drug Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Gilead Sciences Neuraminidase Inhibitors Drug Product Portfolio
  42. 6.7.5 Gilead Sciences Recent Developments
  43. 6.8 Daiichi Sankyo
  44. 6.8.1 Daiichi Sankyo Company Information
  45. 6.8.2 Daiichi Sankyo Business Overview
  46. 6.8.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Portfolio
  48. 6.8.5 Daiichi Sankyo Recent Developments
  49. 6.9 Bristol-Myers Squibb
  50. 6.9.1 Bristol-Myers Squibb Company Information
  51. 6.9.2 Bristol-Myers Squibb Business Overview
  52. 6.9.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Portfolio
  54. 6.9.5 Bristol-Myers Squibb Recent Developments
7 North America
  1. 7.1 North America Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
  3. 7.3 North America Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
  3. 8.3 Europe Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
  3. 10.3 South America Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst